Biocept (NASDAQ:BIOC) Announces Earnings Results

Biocept (NASDAQ:BIOC) announced its earnings results on Wednesday. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.10), MarketWatch Earnings reports. Biocept had a negative return on equity of 268.76% and a negative net margin of 552.54%.

Shares of NASDAQ:BIOC opened at $0.35 on Thursday. The stock has a market capitalization of $28.85 million, a P/E ratio of -0.13 and a beta of -0.89. The stock’s 50-day moving average price is $0.37 and its 200-day moving average price is $0.51. The company has a current ratio of 1.83, a quick ratio of 1.71 and a debt-to-equity ratio of 0.13. Biocept has a 12-month low of $0.21 and a 12-month high of $2.11.

Separately, Maxim Group restated a “buy” rating and set a $1.00 price target on shares of Biocept in a research report on Friday, March 6th.

Biocept Company Profile

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Featured Story: Diversification For Individual Investors

Earnings History for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.